Sep. 24—(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 adults nationwide, is necessary to slow disease progression and help ...
Bronchiectasis is a chronic respiratory disorder characterised by irreversible dilation of the bronchi, leading to impaired mucociliary clearance, recurrent infections and progressive respiratory ...
Panelists discuss how bronchiectasis is more common than previously thought, with growing awareness, research, and specialized centers improving diagnosis and treatment options, though challenges ...
Phenotypes and endotypes in bronchiectasis: a narrative review of progress toward precision medicine
Background and Objective: Bronchiectasis, which was previously regarded as a rare condition, has recently attracted increased attention with advancements in research and therapeutic strategies.
Panelists discuss how emerging DPP1 inhibitor therapies target neutrophil serine proteases to reduce neutrophilic inflammation and neutrophil extracellular trap formation in bronchiectasis. DPP1 ...
— BRINSUPRI, a First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation, Is Available by Prescription Through a Comprehensive Specialty Pharmacy Network — — Insmed (INSM) to Host Investor ...
For adults with a history of smoking and normal spirometry, suspected bronchiectasis is associated with an increased risk for all-cause mortality, according to a study published online Oct. 3 in the ...
The FDA approved oral brensocatib (Brinsupri) as the first treatment for non-cystic fibrosis bronchiectasis in adults and kids 12 years and up, drugmaker Insmed announced on Tuesday. A first-in-class ...
— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10 mg and 25 mg Doses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results